An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will explore potential next-day residual effects of a single evening dose of 3mg of the hypnotic, eszopiclone, 7.5mg of zopiclone, and placebo, in healthy adult subjects.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Eszopiclone; Zopiclone

Criteria

INCLUSION CRITERIA:

• Healthy male and female subjects providing written informed consent.

EXCLUSION CRITERIA:

• Significant medical disorders;

• Sleeping difficulties; alcohol and/or substance abuse;

• Recent use of psychotropic medications, or need to use them during study;

• Very high BMI or very low BMI or bodyweight;

• Known hypersensitivity to the study medications or their excipients;

• Unwilling or unable to meet certain lifestyle or dietary restrictions during the study.